Pathogenesis-directed treatment of linear porokeratosis with topical cholesterol-lovastatin.
Pediatr Dermatol
; 41(2): 296-297, 2024.
Article
em En
| MEDLINE
| ID: mdl-37726979
ABSTRACT
A 2-year-old boy presented with an extensive, asymptomatic, photosensitive eruption refractory to topical steroids and tretinoin; examination and biopsies were consistent with generalized linear porokeratosis involving the face, limbs, and trunk. Treatment with topical cholesterol-lovastatin was initiated, and it successfully improved early erythematous lesions. Whole exome sequencing that targeted mevalonate pathway genes crucial in cholesterol synthesis later revealed a pathogenic, paternally inherited, porokeratosis-associated MVD, c.70+5 G>A, mutation. Topical cholesterol-lovastatin is a safe and effective empiric treatment for porokeratosis when used in the early, erythematous phase, and its success is likely mediated through its role in targeting mevalonate pathway mutations.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Lovastatina
/
Poroceratose
Tipo de estudo:
Etiology_studies
Limite:
Child, preschool
/
Humans
/
Male
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article